You are here

Producing Novel Biosynthetic Therapeutics from Extreme Microbiomes

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911NF-17-C-0076
Agency Tracking Number: C2-0458
Amount: $999,973.99
Phase: Phase II
Program: SBIR
Solicitation Topic Code: CBD152-004
Solicitation Number: 2015.2
Timeline
Solicitation Year: 2015
Award Year: 2017
Award Start Date (Proposal Award Date): 2017-08-30
Award End Date (Contract End Date): 2020-02-23
Small Business Information
601 Genome Way
Huntsville, AL 35806
United States
DUNS: 614372535
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Anuj Singhal
 Director of Drug Discovery
 (256) 655-4342
 anuj.singhal@ixpressgenes.com
Business Contact
 Diana Toh
Phone: (256) 327-9452
Email: diana.toh@ixpressgenes.com
Research Institution
N/A
Abstract

This project is a unique metagenomic evaluation of under-studied extremophilic microbiome natural products (NPs), with the goal of discovering novel antibiotic biowarfare agent (BWA) countermeasures. A metagenomic biosynthetic gene cluster library from extremophilic sources was created, sequenced, analyzed, and exploited to produce several broad-spectrum antibiotic extracts during the Phase I effort. A novel platform for extremophilic microbiome drug discovery (EMDD) was created as well and will be expanded during the Phase II effort. These extracts will be purified and biochemically characterized before testing in vitro against BWAs. Cytotoxicity and mechanism of action studies will be conducted using in vitro and in silico methods. The leads will be optimized by a structure-activity relationship expansion study, which will generate a series of improved analogues for further in vitro screening. The best lead compounds will be tested for in vivo efficacy against priority bacterial BWAs. The goal is to discover a novel antibiotic with efficacy of >50% survival in a lethal challenge mouse model for subsequent preclinical studies and FDA investigational new drug application.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government